Effects Of Candesartan Cilexetil vs Standard Therapy on Serum Levels of Brain Natriuretic Peptide in Patients Suffering From Chronic Heart Failure With Depressed and Preserved Systolic Function.

Trial Profile

Effects Of Candesartan Cilexetil vs Standard Therapy on Serum Levels of Brain Natriuretic Peptide in Patients Suffering From Chronic Heart Failure With Depressed and Preserved Systolic Function.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2013

At a glance

  • Drugs Candesartan cilexetil (Primary) ; Heart failure therapies
  • Indications Chronic heart failure
  • Focus Therapeutic Use
  • Acronyms CANDHEART
  • Sponsors Takeda Italia Farmaceutici
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top